Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2016-01-22 Major Shareholding Noti…
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2016
Major Shareholding Notification
2016-01-22 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically labeled as "Definitive Additional Materials" related to the proxy statement for Arrowhead Research Corporation's annual shareholders meeting. It includes information about voting procedures, meeting date, proposals to be voted on, and instructions for obtaining proxy materials. It does not contain financial statements or detailed financial analysis but serves as materials to solicit shareholder votes. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document length is 6367 characters, which is consistent with a proxy statement or related materials, not a full annual report or earnings release. Therefore, the correct classification is PSI with high confidence.
2016-01-19 English
DEF 14A
Proxy Solicitation & Information Statement
2016-01-19 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes entering into a material definitive agreement (a new lease), an amendment to an existing lease, and creation of a direct financial obligation. There are no financial statements or detailed financial analysis present, only disclosures of agreements and obligations. The document length is 4397 characters, which is relatively short and typical for an 8-K filing. This type of filing is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into more specific categories like Annual Report, Earnings Release, or Capital/Financing Update. It is not a report publication announcement since it contains substantive information about the lease agreement and financial obligation, not just a notice of report availability.
2016-01-14 English
FORM 4 SUBMISSION
Director's Dealing
2016-01-05 English
FORM 4 SUBMISSION
Director's Dealing
2016-01-05 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.